Delivery Order SPE2DB22D9239-SPE2DB24FDL25

Award Date 7/29/24
Potential Completion Date 8/19/24
Potential Value $50K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $86,440.56 contract is for the supply of 3,750 units of the oncology medication Oncaspar (Pegaspargase) in 5 ML vials. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,765.70 contract covers the delivery of 3,750 units of the branded oncology medication Oncaspar (pegaspargase) in 5 mL vials. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program,...
This is a delivery order award to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $49,531.40 firm-fixed-price contract was issued by the Defense Logistics Agency (DLA) on March 19, 2024 and has an ultimate completion date of April 9, 2024. The award is for 4,564,042,836 units of the oncology drug ONCASPAR (pegaspargase) in 5 mL vials. There is no set-aside designation on this contract. DMS Pharmaceutical Group holds an indefinite delivery contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $82,930.72, is for the delivery of 3,750 units of the pharmaceutical product ONCASPAR 3,750 UNIT/5 ML VIAL 5ML. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 3,750 units of the pharmaceutical product ONCASPAR (pegaspargase) in 5 milliliter vials. The delivery order has a potential value of $49,531.40 and a completion date of January 26, 2024. This award is associated with a larger indefinite delivery contract held by DMS Pharmaceutical Group Inc. to supply a variety of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,220.28 firm fixed-price delivery order is for the supply of 4,556,804,056 units of the oncology medication ONCASPAR (pegaspargase) in 5 mL vials. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group, which allows the DLA to issue...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $49,531.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 3,750 units of the prescription drug Oncaspar (asparaginase pegylated) in 5 mL vials. This contract is issued under a larger single-award Indefinite Delivery Contract (IDC) valued at $499,999,999, which enables the DLA to place delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of Oncaspar (pegaspargase) 3,750 unit/5 mL vials. The order, valued at $86,440.56, is a firm fixed-price contract with no set-aside designation. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $49,531.40 contract is for the delivery of 4,562 units of the oncology drug ONCASPAR (3,750 units/5 ml vial) to support the medical supply needs of military healthcare facilities. The award is not associated with a set-aside designation. DMS Pharmaceutical Group holds a larger...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract award of $49,531.40 is for the delivery of 3,750 units of the oncology medication ONCASPAR 3,750 UNIT/5 ML VIAL 5ML. The contract is a firm fixed-price delivery order that does not have a set-aside designation. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDL25
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $49,531.40, is for the delivery of 3,750 units of the drug ONCASPAR (Pegaspargase) in 5 milliliter vials. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which covers a wide range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide. The contract has a period of performance through August 19, 2024 and does not have a set-aside designation.

Generated 10/28/24, 9:43 AM